ProBiotix Health, a pioneer in advanced probiotic science, will spotlight YourBiotixMH and YourBiotixPMH, its range of probiotic-based menopause formulations, at CPHI Frankfurt, at booth #4.1B62.
Designed to support symptom relief and long-term cardiovascular health, ProBiotix has created its YourBiotix formulations to reshape the conversation around menopause, moving the focus from short-term relief to addressing long-term health outcomes for women in the menopause cohort.
At CPHI Frankfurt YourBiotixMH and YourBiotixPMH will break new ground and redefine what menopause support should be. Visitors to the ProBiotix stand will be able to explore the benefits of these pioneering formulations. The event takes place October 28-30, in Germany, and marks the first time ProBiotix Health will be exhibiting at this premium global event.
Redefining the menopause conversation
Steen Andersen, chief operating officer at ProBiotix Health, said: “It is estimated that by the end of 2025, 1,1bn women worldwide will be transitioning through menopause, facing health and wellness challenges that are both physical and emotional. Science shows that post-menopausal women are five times more likely to suffer a heart attack, while 77% of women aged 45 and above have raised cholesterol.
“Most menopause supplements focus on symptom relief, such as hot flushes and sleep disturbance, without targeting these deeper, long-term risks. ProBiotix Health’s new formulations aim to close this gap by supporting women’s health during this important life stage,” Andersen added.
YourBiotixMH and YourBiotixPMH harness the power of ProBiotix Health’s clinically validated probiotic strain LPLDL® (Lactobacillus Plantarum), in combination with selected nutrients that support positive menopause outcomes, such as Isoflavones, Thiamine, and vitamins D and B6.
Unlike most supplements that target only vasomotor symptoms, these are one of the first solutions designed to do more: relieving symptoms and addressing the long-term cardiovascular and bone health risks that accompany menopause.
“This dual focus positions these two products as true next-generation solutions that will allow women to add life to years, not just years to life,” Andersen explained.
The launch also signals a pivotal step in ProBiotix’s wider strategy: to move probiotics beyond their traditional role in digestive health into new products that can target cardiometabolic health and healthy ageing, effectively bridging nutraceutical development with pharma innovation.
“As our awareness of menopause, not just as a transition, but as a turning point in women’s long-term health continues to grow, we are moving beyond symptom management to deliver solutions that safeguard women’s future wellbeing,” Andersen concluded. “The YourBiotix range of finished products reflects our mission to redefine probiotics as powerful tools in cardiometabolic health and healthy ageing, and to bring real innovation to areas of health and wellness where it is needed most.”
The power of YourBiotixMH in transforming women’s health is gaining acclaim throughout the nutraceutical industry. YourBiotixMH was recently named as a finalist in the prestigious NutraIngredients Asia Women’s Health Innovation Award and shortlisted for a WholeFoods Women’s Health Award, further cementing its recognition as a breakthrough product.
For further press inquiries, clinical insights into cutting-edge probiotic science, or to arrange a meeting at CPHI Frankfurt, contact the ProBiotix Health team today https://probiotixhealth.com/contact-us/
